Navigation Links
Novel paclitaxel formulation encouraging for treating advanced lung cancer
Date:6/15/2010

The June edition of the Journal of Thoracic Oncology features a study aimed at determining the optimal dose of the chemotherapy drug nab-paclitaxel with carboplatin as a first-line therapy in patients with non-small cell lung cancer (NSCLC). Results will provide researchers with a data needed to guide a phase 3 trial.

The most commonly used combination treatment for patients with NSCLC is carboplatin plus solvent-based paclitaxel. However, this current treatment has major safety and efficacy concerns, such as severe toxicities, nerve damage. As lung cancer is the leading cause of lung cancer death worldwide, there is a critical need for safe chemotherapy treatments to curb this disease.

In this multi-center study, researchers sought to determine the optimal dose of a chemotherapy treatment using a novel paclitaxel formulation, nanoparticle albuminbound (nab-), which can be administered safely at higher doses than the solvent-based paclitaxel and has performed well when treating breast cancer patients. One hundred seventy-five previously untreated patients were enrolled in the study and received treatment with nab-paclitaxel either on a weekly or every-three-week basis. Dosing levels were also investigated.

Overall results showed response rate was greater in weekly doses than in every-three-week doses. Median progression-free survival was similar between both schedules and ranged from 4.8 to 6.9 months in the every-three-week cohorts and 5.6 to 6.4 months in the weekly cohorts. Overall survival was also similar in both groups and ranged from 8.3 to 14.6 months in the every-three-week cohort and 11.3 to 15.0 in the weekly cohort. Most favorable of all the cohorts was the group receiving 100 mg/m2 weekly nab-paclitaxel. This group achieved a 48 percent response rate with 6.2 and 11.3 months of progression-free survival and overall survival, respectively.

In addition to improved anti-tumor activity, nab-paclitaxel administered weekly was associated with less serious adverse events than when administered every three weeks, with significant reductions of nerve damage and muscle and joint pain. More specifically, it was found that a 100 mg/m2 weekly nab-paclitaxel produced less serious adverse events than other doses.

  Weekly dose  Every-three-week dose 
Response rate 47% 30%
ORR 36-56% 24-40%
 Progression-free survival  5.6-6.4 months 4.8-6.9 months
Overall survival  12.0-15.0 months  8.3-14.6 months

Researchers concluded that nab-paclitaxel plus carboplatin is an effective therapy for advanced NSCLC and recommend a phase 3, randomized, multi-center study comparison 100 mg/m2 weekly nab-paclitaxel plus carboplatin to solvent-based paclitaxel plus carboplatin.

"Given the high cumulative dose delivered and the excellent safety and efficacy profile of the patients who received 100 mg/m2 weekly nab-paclitaxel plus carboplatin, we believe this to be the optimal dosing and schedule for phase 3 comparison in patients with advanced NSCLC," confirms lead investigator Mark A. Socinski, MD of the University of North Carolina Lineberger Comprehensive Cancer Center.


'/>"/>

Contact: Megan Richter
mrichter@spectrumscience.com
202-587-2556
International Association for the Study of Lung Cancer
Source:Eurekalert

Related medicine news :

1. Novel Drug Combats Advanced Melanoma
2. Novel RNA interference screening technique identifies possible path for malignant glioma treatment
3. Novel anti-malarial drug candidate found by UT Southwestern researchers
4. ASCO data highlight novel anti-cancer approach that exposes tumors to immune attack
5. Research identifies patterns of CD24, a novel biomarker for non-small cell lung carcinomas
6. Third European Novel Food Approval Received by Tahitian Noni International
7. Novel nanoparticles prevent radiation damage
8. Novel soy germ-based dietary supplement, SE5-OH containing natural S-Equol, examined for safety and influence on hormones in pre- and post-menopausal women
9. Novel Method Eyed for Normalizing Blood Sugar
10. Novel Parkinson's Treatment Strategy Involves Cell Transplantation
11. MessageSolution First in the Market to Offer All-in-One, Integrated Cloud-Based Archiving for Email, File Systems and SharePoint at Novell BrainShare 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/21/2017)... ... ... Seamild, the largest manufacturer of oats in China, is now aiming at global ... is recognized globally as one of the healthiest cereals, XieQingkui, the founder of Seamild, ... move to sow the seed of good karma. Buddhism spirit featuring benevolence and sacrifice ...
(Date:1/21/2017)... Pekin, IL (PRWEB) , ... January 21, 2017 , ... ... disorders. Even when individuals experience the freedom of recovery, they often feel shame for ... abuse and post-traumatic stress disorder (PTSD). In the workshop, “Rising Strong in Life After ...
(Date:1/20/2017)... ... January 20, 2017 , ... Source Vitál Apothecary, a skin and ... essential oils, announced the company had a successful visit to the 2017 ECRM Diet, ... gives companies that work in the nutritional, sports and health industries a chance to ...
(Date:1/20/2017)... ... January 20, 2017 , ... International Protein, a company based out ... announced it attended the January ECRM trade show in Hilton Head, SC. , ... was determined to create a line of products that would elevate her fitness regime. ...
(Date:1/20/2017)... ... ... “The Angel”: a heartwarming and earnest tale of faith and believing in the ... is the creation of published author, Marjorie Lund-Fontaine, a former professional violinist, alumnus of ... asked of her new book, Marjorie says, “‘The Angel’ was written as a fairytale, ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... , Jan. 19, 2017 Conference Call and Webcast to ... ) today announced it will release results for the fourth quarter ... ... host a conference call at 4:30 PM ET on Wednesday, February ... full year 2016 financial results and other corporate activities. To participate ...
(Date:1/19/2017)... , Jan. 19, 2017 This report ... current and future scenario of the global market. Large ... opioid consumption. Severe chronic constipation is a major side ... traditional laxatives. Hence, novel targeted therapy has been prescribed ... sufferers, launch of targeted medicines, and growing awareness about ...
(Date:1/19/2017)...  Stealth BioTherapeutics Inc. ( Stealth ), a clinical-stage ... announced new additions to its senior leadership team: ... and Daniel Geffken as interim Chief Financial ... , Pharm.D. has been promoted to Chief Clinical Development ... Doug and Daniel to our management team, as both ...
Breaking Medicine Technology: